Advances in gene therapy technologies to treat retinitis pigmentosa
- PMID: 24391438
- PMCID: PMC3878960
- DOI: 10.2147/OPTH.S38041
Advances in gene therapy technologies to treat retinitis pigmentosa
Abstract
Retinitis pigmentosa (RP) is a class of diseases that leads to progressive degeneration of the retina. Experimental approaches to gene therapy for the treatment of inherited retinal dystrophies have advanced in recent years, inclusive of the safe delivery of genes to the human retina. This review is focused on the development of gene therapy for RP using recombinant adenoassociated viral vectors, which show a positive safety record and have so far been successful in several clinical trials for congenital retinal disease. Gene therapy for RP is under development in a variety of animal models, and the results raise expectations of future clinical application. Nonetheless, the translation of such strategies to the bedside requires further understanding of the mutations and mechanisms that cause visual defects, as well as thorough examination of potential adverse effects.
Keywords: AAV; gene therapy; photoreceptor; retinitis pigmentosa.
References
-
- Fletcher EL, Jobling AI, Vessey KA, Luu C, Guymer RH, Baird PN. Animal models of retinal disease. Prog Mol Biol Transl Sci. 2011;100:211–286. - PubMed
-
- Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795–1809. - PubMed
-
- Xu L, Hu L, Ma K, Li J, Jonas JB. Prevalence of retinitis pigmentosa in urban and rural adult Chinese: the Beijing Eye Study. Eur J Ophthalmol. 2006;16(6):865–866. - PubMed
-
- Sen P, Bhargava A, George R, et al. Prevalence of retinitis pigmentosa in South Indian population aged above 40 years. Ophthalmic Epidemiol. 2008;15(4):279–281. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
